Diabetes Metab J.  2013 Aug;37(4):286-290. 10.4093/dmj.2013.37.4.286.

Effect of Granulocyte Colony-Stimulating Factor on the Peripheral Nerves in Streptozotocin-Induced Diabetic Rat

• Lee KA
• Park KT
• Yu HM
• Jin HY
• Baek HS
• Park TS

• KMID: 2174270
• DOI: http://doi.org/10.4093/dmj.2013.37.4.286

Abstract

There are controversial reports about the effect of granulocyte colony-stimulating factor (G-CSF) in peripheral nerve protection. Therefore, the present study aimed to investigate the effect of G-CSF on peripheral nerves in streptozotocin (STZ) induced diabetic rats. After STZ or vehicle injection, rats were divided into five groups (n=6) as follows: normal+vehicle, normal+G-CSF (50 microg/kg for 5 days), diabetes mellitus (DM)+vehicle, DM+G-CSF (50 microg/kg for 5 days), and DM+G-CSF extension (50 microg/kg for 5 days and followed by two injections per week up to 24 weeks). Our results showed that the current perception threshold was not significantly different among experimental groups. G-CSF treatment inhibited the loss of cutaneous nerves and gastric mucosal small nerve fibers in morphometric comparison, but statistical significance was not observed. The present results demonstrated that G-CSF has no harmful but minimal beneficial effects with respect to peripheral nerve preservation in diabetic rats.

Keyword

Diabetes mellitus; Granulocyte colony-stimulating factor; Peripheral nerves

MeSH Terms

Animals
Diabetes Mellitus
Granulocyte Colony-Stimulating Factor
Granulocytes
Nerve Fibers
Peripheral Nerves
Rats
Streptozocin
Granulocyte Colony-Stimulating Factor
Streptozocin

Figure

• 

  Fig. 1 (A) Intraepidermal nerve fiber density (IENFD) on the dorsum of the foot at 24 weeks and (B) morphologic pattern of antiprotein gene product 9.5-positive small nerve fibers. IENFDs in the granulocyte colony-stimulating factor (G-CSF) treated diabetic groups were preserved compared with nontreated diabetic group, although statistical significance was not observed. Horizontal bar indicates 100 µm. DM, diabetes mellitus. aP<0.05 compared to normal group.

• 

  Fig. 2 (A) The average number of mucosal nerve fibers and (B) antiprotein gene product 9.5-positive small nerve fibers in stomach. The nerve count was markedly decreased in the diabetic group. Granulocyte colony-stimulating factor (G-CSF) treated diabetic groups were preserved compared with non-treated diabetic group, although statistical significance was not observed. Horizontal bar indicates 100 µm. DM, diabetes mellitus. aP<0.05 compared to normal group.

Reference

1. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood. 1991. 78:2791–2808.

2. Pan HC, Cheng FC, Lai SZ, Yang DY, Wang YC, Lee MS. Enhanced regeneration in spinal cord injury by concomitant treatment with granulocyte colony-stimulating factor and neuronal stem cells. J Clin Neurosci. 2008. 15:656–664.

3. Pan HC, Chen CJ, Cheng FC, Ho SP, Liu MJ, Hwang SM, Chang MH, Wang YC. Combination of G-CSF administration and human amniotic fluid mesenchymal stem cell transplantation promotes peripheral nerve regeneration. Neurochem Res. 2009. 34:518–527.

4. Lu CZ, Xiao BG. G-CSF and neuroprotection: a therapeutic perspective in cerebral ischaemia. Biochem Soc Trans. 2006. 34(Pt 6):1327–1333.

5. Meuer K, Pitzer C, Teismann P, Kruger C, Goricke B, Laage R, Lingor P, Peters K, Schlachetzki JC, Kobayashi K, Dietz GP, Weber D, Ferger B, Schabitz WR, Bach A, Schulz JB, Bahr M, Schneider A, Weishaupt JH. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease. J Neurochem. 2006. 97:675–686.

6. Liou JT, Lui PW, Liu FC, Lai YS, Day YJ. Exogenous granulocyte colony-stimulating factor exacerbate pain-related behaviors after peripheral nerve injury. J Neuroimmunol. 2011. 232:83–93.

7. Campbell IK, Rich MJ, Bischof RJ, Hamilton JA. The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF. J Leukoc Biol. 2000. 68:144–150.

8. Gordois A, Scuffham P, Shearer A, Oglesby A, Tobian JA. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003. 26:1790–1795.

9. Cunha JM, Funez MI, Cunha FQ, Parada CA, Ferreira SH. Streptozotocin-induced mechanical hypernociception is not dependent on hyperglycemia. Braz J Med Biol Res. 2009. 42:197–206.

10. Jin HY, Liu WJ, Park JH, Baek HS, Park TS. Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats. Arch Med Res. 2009. 40:536–544.

11. Doupis J, Lyons TE, Wu S, Gnardellis C, Dinh T, Veves A. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab. 2009. 94:2157–2163.

12. Apfel SC. Neurotrophic factors and diabetic peripheral neuropathy. Eur Neurol. 1999. 41:Suppl 1. 27–34.

13. Pan HC, Wu HT, Cheng FC, Chen CH, Sheu ML, Chen CJ. Potentiation of angiogenesis and regeneration by G-CSF after sciatic nerve crush injury. Biochem Biophys Res Commun. 2009. 382:177–182.

14. Chao PK, Lu KT, Lee YL, Chen JC, Wang HL, Yang YL, Cheng MY, Liao MF, Ro LS. Early systemic granulocyte-colony stimulating factor treatment attenuates neuropathic pain after peripheral nerve injury. PLoS One. 2012. 7:e43680.